Business Standard

Wednesday, December 25, 2024 | 06:30 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

India's first Covid cure Vincov-19 completes second phase clinical trial

These highly purified antibody fragments have a high neutralising capacityagainst the Sars-CoV-2 virus

vaccine
Premium

Phase 2 Clinical Trials were conducted across multiple centres in India and included over 200 patients. Representational image

Sohini Das Mumbai
India’s first “antidote” and “cure” against the Sars-CoV-2 virus may soon hit the market if the Phase 3 trials of VINCOV-19 go well. An antibody therapy derived from horse serum, VINCOV-19 has successfully completed the Phase 2 clinical trials, announced University of Hyderabad (UoH) and CSIR-Centre for Cellular & Molecular Biology (CCMB) in collaboration with VINS Bioproducts, an immunological company.

VINCOV-19 is now ready for market authorisation and simultaneous Phase 3 clinical trials, the firm said in a press statement.

Siddharth Daga, chief executive officer, VINS Bioproducts, said: “Phase 2 clinical trials of VINCOV-19 have been very successful. VINCOV-19 is

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in